AveXis (AveXis) Interest Coverage : No Debt ⁽¹⁾ (As of Mar. 2018)

View and export this data going back to 2016. Start your Free Trial

What is AveXis Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. AveXis's Operating Income for the three months ended in Mar. 2018 was $-222.46 Mil. AveXis's Interest Expense for the three months ended in Mar. 2018 was $0.00 Mil. AveXis has no debt. The higher the ratio, the stronger the company's financial strength is.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for AveXis's Interest Coverage or its related term are showing as below:

AVXS's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 127.155
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

AveXis Interest Coverage Historical Data

The historical data trend for AveXis's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

AveXis Interest Coverage Chart

AveXis Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Interest Coverage

No Debt

AveXis Quarterly Data
	Dec13	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18
Interest Coverage	Get a 7-Day Free Trial										No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of AveXis's Interest Coverage

For the Biotechnology subindustry, AveXis's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AveXis's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AveXis's Interest Coverage distribution charts can be found below:

* The bar in red indicates where AveXis's Interest Coverage falls into.

AveXis Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

AveXis's Interest Coverage for the fiscal year that ended in Dec. 2017 is calculated as

Here, for the fiscal year that ended in Dec. 2017, AveXis's Interest Expense was $0.00 Mil. Its Operating Income was $-220.37 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

AveXis had no debt ⁽¹⁾.

AveXis's Interest Coverage for the quarter that ended in Mar. 2018 is calculated as

Here, for the three months ended in Mar. 2018, AveXis's Interest Expense was $0.00 Mil. Its Operating Income was $-222.46 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

AveXis had no debt ⁽¹⁾.

The higher the ratio, the stronger the company's Financial Strength is.

AveXis (NAS:AVXS) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

AveXis Interest Coverage Related Terms

Thank you for viewing the detailed overview of AveXis's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

AveXis (AveXis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AveXis Inc (NAS:AVXS) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.avexis.com

AveXis Inc is a United States-based clinical-stage gene therapy company. It is engaged in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its product candidate, AVXS-101, is a gene therapy product candidate in Phase 1 clinical trial for the treatment of spinal muscular atrophy, or SMA, Type 1, the genetic cause of infant mortality. AVXS-101 is designed to deliver a fully functional human survival motor neuron gene into the nuclei of motor neurons that then generates an increase in survival motor neuron protein levels. The company believes this will result in improved motor neuron function and patient outcomes.

Executives

Sean P. Nolan	director, officer: President & CEO	C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Session R.a. Ii	officer: Sr. VP, Corp Strategy	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Paul B Manning	director, other: Former 10% Owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Sukumar Nagendran	officer: Sr. VP & Chief Medical Officer	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Frank Verwiel	director	C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
James J Litalien	officer: SrVP/Chief Reg&Quality Officer	C/O SOMAXON PHARMACEUTICALS, INC., 3721 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO CA 92130
Daniel G Welch	director	4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
Rick Modi	officer: Chief Business Officer	C/O AVEXIS INC, 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Phillip B. Donenberg	officer: Chief Financial Officer	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Joao Md Siffert	director	20 ENTERPRISE, SUITE 200, ALISO VIEJO CA 92656
Ag Novartis	10 percent owner	LICHTSTRASSE 35, BASEL V8 CH 4056
Bong Y Koh	director	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Terrence C Kearney	director	IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045
Deerfield International Master Fund, L.p.	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
James E Flynn	director, 10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017